Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
Comprehensive summary of latest evidence on C-peptide and evolving therapies
Written by renowned international experts in the field
Covers both research and clinical issues, including inflammation, cardiovascular complications, neuropathy and nephropathy
In Diabetes & C-Peptide: Scientific and Clinical Aspects, a renowned group of leading researchers and physicians offers a comprehensive overview of the role of C-Peptide in type 1 diabetes. The book is organized in five sections. An Introductory section provides the background and key features of C-peptide’s physiological function and how its deficiency contributes to complications. The second section describes up-to-date information on the biochemical and molecular actions of C-peptide, including membrane binding, interactions with insulin as well as the interaction between C-peptide and zinc and effects on microvascular vasoreactivity. The third section summarizes in vivo animal studies of the type 1 diabetic complications. The fourth section reviews the clinical efforts of C-peptide on inflammation, cardiovascular complication, neuropathy and nephropathy. Finally, in the Conclusions section, a summary of the present state of C-peptide, outstanding questions, and the likely direction of the field are offered. Developed by the foremost investigators in the rapidly moving field of C-peptide research, Diabetes & C-Peptide: Scientific and Clinical Aspects is an important contribution to the literature for all researchers and physicians concerned about type 1 diabetes.